期刊文献+

卵巢透明细胞癌中pVHL的诊断价值和意义 被引量:1

Diagnostic value and significance of pVHL in ovarian clear cell carcinoma
下载PDF
导出
摘要 目的观察p VHL在卵巢不同类型上皮性癌中的表达,探讨p VHL在卵巢透明细胞癌诊断价值。方法采用免疫组化En Vision法检测卵巢恶性上皮性癌p VHL的表达。结果 20例卵巢透明细胞癌均弥漫强(+),阳性率为90%;20例卵巢高级别浆液性癌中3例p VHL呈胞质/胞膜(+),阳性率15%;14例卵巢高-中分化宫内膜样腺癌有2例(+),阳性率14.3%,p VHL在浆液性癌和子宫内膜样腺癌中的阳性率明显低于透明细胞癌(p<0.01)。p VHL对卵巢透明细胞癌的敏感性90%,特异性85.2%。结论 p VHL是一种敏感性高的卵巢透明细胞癌标记物,p VHL弥漫强(+)有助于辅助诊断卵巢透明细胞癌,具有潜在的临床价值。 Objective To study the expression of von Hippel-Lindau( p VHL) in different types of ovarian carcinomas and to explore the diagnostic value of p VHL in ovarian clear cell carcinomas. Methods Immunohistochemical En Vision method was used to detect the expression in ovarian malignant epithelial carcinom. Results 20 clear cell carcinomas were almost diffusely strong expression of p VHL,and the positive rate was 90%. In 20 cases of ovarian high grade serous carcinoma,p VHL was cytoplasmic/membranous positive expression in 3 cases,the positive rate was 15%. 2 of 14 cases of ovarian moderately/well differentiated endometrioid adenocarcinoma were positively expressed,and the positive rate was14. 3%. The expression of p VHL in serous carcinoma and endometrioid adenocarcinoma was significantly lower than that in ovarian clear cell carcinoma; the difference was statistical significance( P〈 0. 01). The sensitivity and specificity of p VHL in the diagnosis of ovarian clear cell carcinoma were about 90% and 85. 2%,respectively. Conclusion p VHL may be a highly sensitive marker of ovarian clear cell carcinoma. The overexpression of p VHL may be helpful in the diagnosis of ovarian clear cell carcinomas and it has potential clinical value.
出处 《诊断病理学杂志》 2017年第11期841-843,847,共4页 Chinese Journal of Diagnostic Pathology
关键词 卵巢肿瘤 透明细胞癌 p VHL 免疫组织化学染色 Ovarianneoplasm Clear cell carcinomas pVHL Immunohistochemical staining
  • 相关文献

参考文献1

二级参考文献13

  • 1任凤岩,王丹波,姜彦多,张淑兰.卵巢透明细胞癌及其合并子宫内膜异位症的临床及病理分析[J].中国全科医学,2007,10(17):1416-1419. 被引量:6
  • 2Crotzer DR, Sun CC, Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol, 2007, 105:404-408.
  • 3Pather S, Quinn MA. Clear-cell cancer of the ovary-is it chermsnsitive? Int J Gynecol Cancer, 2005, 15:432-437.
  • 4Polverino G, Parazzirfi F, Stellato G, et al. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gyneeol Oncol, 2005, 99:343-347.
  • 5Itamochi H, Kigawa J, Sultana H, et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res, 2002, 93:723-728.
  • 6Fujimura M, Katsumata N, Tsuda H, et al. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res, 2002, 93 : 1250- 1257.
  • 7Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res, 2002, 8:2448-2454.
  • 8Chatzistamou I, Schally AV, Szepeshazi K, et al. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC- 3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Lett, 2001, 171:37-45.
  • 9Arencibia JM, Bajo AM, Schally AV, et al. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anticancer Drugs, 2002, 13:949-956.
  • 10马绍康,张宏图,吴令英,刘丽影.88例卵巢透明细胞癌临床及预后分析[J].中华肿瘤杂志,2007,29(10):784-788. 被引量:11

共引文献9

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部